Published in Eur J Nucl Med Mol Imaging on March 21, 2009
Incidental findings on positron emission tomography/CT scans performed in the investigation of lung cancer. Br J Radiol (2012) 0.81
Significance of Incidental Nasopharyngeal Uptake on (18)F-FDG PET/CT: Patterns of Benign/Physiologic Uptake and Differentiation from Malignancy. Nucl Med Mol Imaging (2014) 0.77
Is integrated 18F-FDG PET/MRI superior to 18F-FDG PET/CT in the differentiation of incidental tracer uptake in the head and neck area? Diagn Interv Radiol (2017) 0.75
The respiratory burst of phagocytes. J Clin Invest (1984) 3.86
Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA (2003) 3.45
Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med (1992) 3.31
18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol (2005) 2.78
Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol (2004) 2.23
Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med (1996) 1.99
False-positive FDG PET uptake--the role of PET/CT. Eur Radiol (2005) 1.97
Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med (1996) 1.95
PET/CT: form and function. Radiology (2007) 1.89
PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics (2004) 1.88
Management of oral mucositis in patients who have cancer. Dent Clin North Am (2008) 1.72
Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab (2003) 1.61
Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology (2005) 1.61
Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology (2004) 1.60
To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med (2004) 1.51
Impact of metallic dental implants on CT-based attenuation correction in a combined PET/CT scanner. Eur Radiol (2002) 1.41
Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging (2003) 1.31
Software volumetric evaluation of doubling times for differentiating benign versus malignant pulmonary nodules. AJR Am J Roentgenol (2006) 1.28
18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope (2005) 1.28
Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med (1999) 1.24
Prevalence and patterns of physiologic muscle uptake detected with whole-body 18F-FDG PET. J Nucl Med Technol (2006) 1.23
Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas. Otolaryngol Head Neck Surg (2007) 1.16
Combined PET-CT in the head and neck: part 1. Physiologic, altered physiologic, and artifactual FDG uptake. Radiographics (2005) 1.16
Skeletal muscle uptake of fluorine-18-FDG: effect of oral diazepam. J Nucl Med (1996) 1.14
Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging (2008) 1.09
Augmented 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C. J Nucl Med (2004) 1.06
Head and neck imaging with PET and PET/CT: artefacts from dental metallic implants. Eur J Nucl Med Mol Imaging (2002) 1.05
Impact of combined (18)F-FDG PET/CT in head and neck tumours. Br J Cancer (2005) 1.04
The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2006) 1.01
Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology (2004) 1.01
Current status of FDG-PET for head and neck cancer. J Surg Oncol (2008) 0.99
Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2006) 0.98
Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med (2004) 0.97
Utility of 18F-FDG PET/CT uptake patterns in Waldeyer's ring for differentiating benign from malignant lesions in lateral pharyngeal recess of nasopharynx. J Nucl Med (2007) 0.96
Standardized uptake values of normal organs on 18F-fluorodeoxyglucose positron emission tomography and computed tomography imaging. J Int Med Res (2007) 0.96
Diffuse and diffuse-plus-focal uptake in the thyroid gland identified by using FDG-PET: prevalence of thyroid cancer and Hashimoto's thyroiditis. Ann Nucl Med (2007) 0.96
Accuracy of 18F-FDG-PET/CT for staging of oral squamous cell carcinoma. Head Neck (2008) 0.93
Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. Br J Radiol (2007) 0.93
Significance of incidental fluorodeoxyglucose uptake in the parotid glands and its impact on patient management. Nucl Med Commun (2008) 0.92
Standardized uptake value atlas: characterization of physiological 2-deoxy-2-[18F]fluoro-D-glucose uptake in normal tissues. Mol Imaging Biol (2007) 0.88
Immunology of the tonsil: a review. J R Soc Med (1990) 0.87
F-18-FDG-PET in a patient with Hashimoto's thyroiditis and MALT lymphoma recurrence of the thyroid. Wien Med Wochenschr (2003) 0.85
FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET finding. Nuklearmedizin (2005) 0.84
Role of 18FFDG PET/CT in the treatment of head and neck cancers: posttherapy evaluation and pitfalls. AJR Am J Roentgenol (2005) 0.82
[Normal variants and frequent pitfalls with (18)FDG PET/CT study]. Cir Cir (2008) 0.81
Evaluation of normal FDG uptake in palatine tonsil and its potential value for detecting occult head and neck cancers: a PET CT study. Nucl Med Commun (2007) 0.80
Physiological FDG uptake in the palatine tonsils. Ann Nucl Med (2001) 0.78
Role of 18FFDG PET/CT in the treatment of head and neck cancers: principles, technique, normal distribution, and initial staging. AJR Am J Roentgenol (2005) 0.77
[How much CT does PET/CT need?]. Nuklearmedizin (2004) 0.75
FDG-PET in head and neck, and thyroid cancer. Chang Gung Med J (2005) 0.75
Head and neck cancer: carcinoma of unknown primary. Top Magn Reson Imaging (2007) 0.75
Excretion of FDG into saliva and its significance for PET imaging. Nuklearmedizin (2002) 0.75
Intense FDG uptake in a benign Hurthle cell adenoma. Clin Nucl Med (2004) 0.75
[Whole-body tumor staging: MRI or FDG-PET/CT?]. Radiologe (2004) 0.75
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA (2003) 3.45
Euthyroid goiter with and without nodules--diagnosis and treatment. Dtsch Arztebl Int (2012) 2.79
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke (2014) 2.71
A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the Wingspan study. Stroke (2007) 2.70
Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging (2009) 2.67
Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology (2010) 2.60
Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol (2004) 2.23
Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation (2010) 2.14
False-positive FDG PET uptake--the role of PET/CT. Eur Radiol (2005) 1.97
Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis (2006) 1.91
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med (2004) 1.91
Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology (2003) 1.90
Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol (2011) 1.89
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer (2005) 1.73
Treatment of wide-necked intracranial aneurysms with a self-expanding stent system: initial clinical experience. AJNR Am J Neuroradiol (2003) 1.62
Double-stent method: therapeutic alternative for small wide-necked aneurysms. Technical note. J Neurosurg (2004) 1.62
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging (2010) 1.61
Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol (2007) 1.59
Year-round tracking of small trans-Saharan migrants using light-level geolocators. PLoS One (2010) 1.57
Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res (2006) 1.57
Imaging of patients with hippocampal sclerosis at 7 Tesla: initial results. Acad Radiol (2009) 1.54
Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med (2012) 1.53
To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med (2004) 1.51
High-profile flow diverter (silk) implantation in the basilar artery: efficacy in the treatment of aneurysms and the role of the perforators. Stroke (2010) 1.51
¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging (2012) 1.50
Short term effects of magnetic resonance imaging on excitability of the motor cortex at 1.5T and 7T. Acad Radiol (2009) 1.50
European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis (2013) 1.50
Unknown primary tumors: detection with dual-modality PET/CT--initial experience. Radiology (2004) 1.48
Shortcomings and promises of recent carotid-stenting trials. Lancet Neurol (2007) 1.44
Segmentation of PET volumes by iterative image thresholding. J Nucl Med (2007) 1.43
MR-based attenuation correction for torso-PET/MR imaging: pitfalls in mapping MR to CT data. Eur J Nucl Med Mol Imaging (2008) 1.42
Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging (2009) 1.41
Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging (2003) 1.31
Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA (2006) 1.29
Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med (2008) 1.28
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol (2013) 1.27
Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med (2004) 1.27
68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med (2011) 1.27
Cell-free production of G protein-coupled receptors for functional and structural studies. J Struct Biol (2007) 1.24
Stents for intracranial wide-necked aneurysms: more than mechanical protection. Neuroradiology (2008) 1.22
Timing of conditioned eyeblink responses is impaired in cerebellar patients. J Neurosci (2005) 1.22
Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. Eur J Radiol (2013) 1.19
Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol (2003) 1.17
Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging (2010) 1.17
Health-related Quality of Life, depression and anxiety in thyroid cancer patients. Qual Life Res (2006) 1.14
Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med (2008) 1.14
Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med (2002) 1.13
Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. Gastroenterology (2010) 1.12
Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab (2002) 1.10
Np9 protein of human endogenous retrovirus K interacts with ligand of numb protein X. J Virol (2004) 1.09
Three-dimensional delayed gadolinium-enhanced magnetic resonance imaging of hip joint cartilage at 3T: a prospective controlled study. Eur J Radiol (2012) 1.09
Evaluation of brain injury after coronary artery bypass grafting. A prospective study using neuropsychological assessment and diffusion-weighted magnetic resonance imaging. Eur J Cardiothorac Surg (2004) 1.09
The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg (2010) 1.09
Imaging of adult astrocytic brain tumours with 7 T MRI: preliminary results. Eur Radiol (2009) 1.08
The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab (2004) 1.08
Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. J Surg Oncol (2008) 1.08
Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET. Eur J Nucl Med Mol Imaging (2007) 1.08
Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med (2012) 1.08
Brain tissue water uptake after middle cerebral artery occlusion assessed with CT. J Neuroimaging (2004) 1.08
Cross-modal plasticity in deaf subjects dependent on the extent of hearing loss. Brain Res Cogn Brain Res (2005) 1.07
Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging (2007) 1.07
Positron emission tomography/computed tomography--imaging protocols, artifacts, and pitfalls. Mol Imaging Biol (2004) 1.07
Peripheral neuropathy: assessment of proximal nerve integrity by diffusion tensor imaging. Muscle Nerve (2013) 1.06
Endovascular treatment of unruptured intracranial aneurysms. AJNR Am J Neuroradiol (2002) 1.05
Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group. Cancer Imaging (2012) 1.05
Dual-energy-CT of hypervascular liver lesions in patients with HCC: investigation of image quality and sensitivity. Eur Radiol (2010) 1.05
Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol (2013) 1.05
Secondary rise in blood pressure after renal denervation. Lancet (2012) 1.04
Small ischemic brain lesions after cardiac valve replacement detected by diffusion-weighted magnetic resonance imaging: relation to neurocognitive function. Eur J Cardiothorac Surg (2005) 1.04
Update on neuroimaging in infectious central nervous system disease. Curr Opin Neurol (2004) 1.04
MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. Eur Radiol (2014) 1.04
Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach? Dig Dis Sci (2008) 1.03
Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab (2009) 1.03